APPROACHES TOWARD VACCINE DEVELOPMENT FOR COVID 19

2020-09-10 2020-09-15 2020-09-20 3/13/2025 2:37:37 AM Journal of Applied Pharmacy 12 2020 Conference abstract 98 99 2020 http://dx.doi.org/10.21065/19204159.pharm.alazhar English Mohamed Ahmed Ahmed Ali Coronaviruses are belonging to a large family most of them are animal viruses except 6 of them cross the species barrier to infect human. At the beginning of the 21th century SARS- CoV1 was emerged and controlled followed by Middle East Respiratory Syndrome CoV (MERS-CoV) which still circulating in the Arabian Peninsula and by the end of 2019 the new SARS-CoV was emerged with high potential for transmission globally. The risk of the SARS- CoV2 is being in the novelty of the virus where the similarity of SARS CoV2 with MERS-CoV is ~51.8% and with SARSCoV1 is 79% and the second issue is the rapid transmission of the virus. To control this rapid transmitted virus, we have to develop a candidate vaccine, and this is what the researchers do in many countries including Egypt. Our approaches to develop candidate vaccines are i) Virus vectorbased vaccine; ii) DNA vaccine ; iii) the recombinant DNA constructs which prepared in approach II were used to express the corresponding peptides (S1,S,S2,RBD &N) and IV) Whole virus inactivated candidate vaccine